Skip to main content
main-content

Nephropathy

News

09-20-2019 | Nephropathy | EASD 2019 | News

Mixed results for PRIORITY diabetic nephropathy trial

The CKD273 proteomic biomarker panel can predict which people with type 2 diabetes will develop detectable diabetic nephropathy, but early intervention with spironolactone does not mitigate this risk, report the PRIORITY investigators.

09-09-2019 | Nephropathy | News

Meta-analysis supports use of SGLT2 inhibitors to prevent kidney failure

Findings from a systematic review and meta-analysis suggest that SGLT2 inhibitors reduce the risk for major adverse kidney outcomes among people with type 2 diabetes, regardless of baseline kidney function.

09-03-2019 | Retinopathy | News

Microvascular benefits of lowest HbA1c target in type 1 diabetes questioned

Aiming for the lowest international targets in glycated hemoglobin levels may not protect against retinopathy and nephropathy in patients with type 1 diabetes, research suggests.

06-13-2019 | Dapagliflozin | ADA 2019 | News

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

06-12-2019 | Canagliflozin | ADA 2019 | News

Canagliflozin benefits span multiple cardiovascular backgrounds

Canagliflozin reduces the risk for major cardiovascular events and kidney failure versus placebo in patients with type 2 diabetes and chronic kidney disease with and without a known history of cardiovascular disease, CREDENCE study data show.

06-09-2019 | Semaglutide | ADA 2019 | News

PIONEER trials test oral semaglutide in moderate renal impairment, flexible dosing

The PIONEER 5 and 7 trials show the efficacy of oral semaglutide in people with moderate renal impairment and the potential for a flexible dosing regimen.

06-09-2019 | Type 2 diabetes | ADA 2019 | News

Short-term delays in diabetes onset confer long-term cardioprotective effects

Delaying diabetes onset by at least 6 years in people with impaired glucose tolerance significantly reduces their risk for cardiovascular disease and microvascular complications, show 30-year data from the Da Qing Diabetes Prevention Study.

04-17-2019 | Nephropathy | News

SONAR results support atrasentan for preserving renal function in type 2 diabetes

The endothelin receptor antagonist atrasentan may reduce the risk for kidney disease progression among certain high-risk patients with type 2 diabetes and kidney disease, indicate findings from the SONAR trial.

04-16-2019 | Nephropathy | News

Dapagliflozin–saxagliptin 'attractive' for type 2 diabetes with kidney disease

Dapagliflozin, with or without saxagliptin, reduces albuminuria in people with type 2 diabetes and moderate-to-severe chronic kidney disease when used in combination with antihypertensive treatments, DELIGHT study data show.

04-15-2019 | Nephropathy | Highlight | News

Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.

04-05-2019 | Nephropathy | News

Variable renal trajectories may complicate type 2 diabetes prescribing

People with type 2 diabetes experience an overall decline in renal function over time, but there is substantial variation among individuals, with some seeing an improvement in estimated glomerular filtration rate, researchers report.

03-21-2019 | Heart failure | News

Microvascular disease a marker of heart failure risk in type 2 diabetes

The presence of microvascular disease in people with type 2 diabetes signals a high risk for heart failure, report the EMPA-REG OUTCOME investigators.

03-04-2019 | SGLT2 inhibitors | News

Meta-analysis confirms SGLT2 inhibitor heart failure, kidney disease benefits

Sodium-glucose cotransporter-2 inhibitors have a greater effect than glucagon-like peptide-1 receptor agonists on reducing hospitalization for heart failure and kidney disease progression in patients with type 2 diabetes, according to the findings of a systematic review and meta-analysis.

02-04-2019 | Complications | News

Microvascular complications do not interact to raise mortality in type 1 diabetes

All-cause mortality risk in patients with type 1 diabetes and more than one microvascular complication does not exceed the combined risk estimates of each separate complication, Danish researchers report.

01-09-2019 | Nephropathy | News

Albuminuria backed as kidney disease treatment response marker

The results of two individual patient data meta-analyses support albuminuria as a surrogate marker of treatment response in patients with chronic kidney disease, particularly those with high baseline albuminuria.

11-22-2018 | Nephropathy | News

International variation in ESRD, non-ESRD deaths in type 1 diabetes highlighted

The risk for end-stage renal disease is high among patients with type 1 diabetes and advanced nephropathy but varies by country, shows an analysis of cohorts from Finland, France, Denmark, and the USA.

11-14-2018 | Nephropathy | News

Ischemic heart disease biggest threat to type 1 diabetes patients after kidney transplant

Kidney transplantation greatly reduces mortality risk in people with type 1 diabetes and end-stage renal disease, but premature death from ischemic heart disease remains common, report researchers.

11-10-2018 | Dapagliflozin | Highlight | News

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

11-09-2018 | Adolescents | News

Elevated multiple complication risk in youth with type 1 diabetes

Patients with type 1 diabetes may develop multiple complications even before they reach adulthood, shows an analysis of the SEARCH for Diabetes in Youth Study.

11-08-2018 | Nephropathy | News

Novel VAP-1 inhibitor shows promise for diabetic kidney disease

The novel, orally active vascular adhesion protein-1 inhibitor ASP8232 effectively reduces albuminuria, with few side effects, in patients with type 2 diabetes and chronic kidney disease, phase II study data show.

10-17-2018 | Liraglutide (T2DM) | News

Cardiovascular benefits of liraglutide in type 2 diabetes apply to high-risk subgroups

The cardioprotective effects of liraglutide apply to patients with chronic kidney disease as well as those with established cardiovascular disease, show two post-hoc analyses of the LEADER trial.

10-12-2018 | Prognosis | EASD 2018 | News

Simple clinical measures may be better prognosticators than proposed diabetes subgroups

The recently proposed five diabetes subgroups are reproducible, but are more complicated and no better than simple clinical variables for predicting disease progression and treatment response, researchers have reported.

09-19-2018 | SGLT2 inhibitors | News

No increased AKI risk for SGLT2 inhibitors in real-world setting

Real-world study data confirm that sodium glucose cotransporter 2 inhibitors do not significantly increase the risk for acute kidney injury compared with dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes.

08-15-2018 | Nephropathy | News

High-normal ACR predicts renal damage in adolescents with diabetes

Having an albumin-to-creatinine ratio at the upper end of the normal range predicts microalbuminuria and cardiovascular risk in adolescents with type 1 diabetes, say the AdDIT investigators.

08-06-2018 | Metabolic surgery | Highlight | News

Real-world bariatric surgery data show microvascular protection

Obese patients with type 2 diabetes who undergo bariatric surgery achieve large reductions in their risk for microvascular complications, shows a real-world study.

07-30-2018 | Nephropathy | News

Isolated eGFR reduction confers significant mortality risk in type 2 diabetes

Renal impairment, even in the absence of albuminuria, is a strong predictor of mortality in patients with type 2 diabetes, shows a large prospective study.

07-17-2018 | Primary care | News

HbA1c valid marker of blood glucose in anemia or CKD

The presence of mild-to-moderate anemia or chronic kidney disease does not have a clinically significant effect on the interpretation of glycated hemoglobin as a marker of glycemic control, Danish research shows.

07-10-2018 | Canagliflozin | News

CANVAS analysis supports canagliflozin CV benefit at low renal function

A secondary analysis of the CANVAS trial supports the beneficial cardiovascular and renal effects of sodium-glucose cotransporter 2 inhibition down to a low level of kidney function.

07-03-2018 | Canagliflozin | News

CANVAS data support renoprotective effect of canagliflozin in type 2 diabetes

Canagliflozin reduces the risk for loss of kidney function, estimated glomerular filtration rate decline, and albuminuria versus placebo in people with type 2 diabetes at high risk for cardiovascular events, CANVAS Program data show.

06-18-2018 | Dulaglutide | News

Dulaglutide feasible alternative to insulin glargine in patients with CKD

Once-weekly dulaglutide lowers glycated hemoglobin levels to a similar degree to titrated daily insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease, study findings indicate.

06-13-2018 | Nephropathy | News

Dapagliflozin of value in type 2 diabetes with moderate kidney impairment

Twenty-four weeks of treatment with dapagliflozin significantly improves glycemic control, body weight and systolic blood pressure in patients with type 2 diabetes and moderate kidney impairment, phase III study data show.

06-12-2018 | Metformin | News

Cautious metformin use supported with moderately reduced renal function

The risk for acidosis during metformin treatment is no higher than that during alternative treatment among patients with type 2 diabetes and an estimated glomerular filtration rate below 30 mL/min per 1.73 m2, study data show.

06-04-2018 | Nephropathy | News

Modifiable factors important in diabetes-related kidney decline

Findings from the ARIC cohort show that diabetes increases the rate of long-term kidney function decline, but a proportion of this is accounted for by modifiable risk factors.

05-30-2018 | Nephropathy | News

Hyperkalemia common, linked to poor outcomes in diabetes

A population-based study shows that hyperkalemia is common in people with diabetes, and is associated with hospital admissions and mortality risk.

05-14-2018 | Nephropathy | News

Real-world data support intensive risk factor control in diabetes patients with CKD

Data from primary care indicate that more successful control of vascular risk factors in patients with type 2 diabetes and chronic kidney disease is associated with reduced risk for cardiovascular disease and mortality.

04-27-2018 | Nephropathy | Highlight | News

Renal risk associated with intensive BP treatment in type 2 diabetes

Research shows that intensive blood pressure control increases the risk for new-onset chronic kidney disease, particularly in patients with type 2 diabetes, creating a potential treatment dilemma.

04-18-2018 | Nephropathy | News

Neprilysin inhibition appears beneficial in diabetic kidney disease

Secondary analysis of the PARADIGM-HF trial shows that the adverse effects of diabetes on kidney function can be ameliorated by a neprilysin inhibitor.

04-06-2018 | Nephropathy | News

Ethnicity, younger age linked to adverse outcomes in diabetic kidney disease

Ethnicity is associated with declining renal function and mortality risk among patients with diabetic kidney disease, and younger patients have the highest risk for rapid disease progression, researchers report.

03-26-2018 | Complications | News

Diabetes duration, control impact cause-specific mortality in Mexico

Deaths from vascular, renal, and infectious causes substantially increase with increasing diabetes duration and worsening glycemic control, results of the Mexico City Prospective Study show.

03-16-2018 | SGLT2 inhibitors | News

eGFR within normal range predictive of SGLT2 inhibitor response

Kidney function predicts patients’ response to SGLT2 inhibitors even in patients with normal estimated glomerular filtration rate, show real-world data.

03-02-2018 | Prediabetes | Highlight | News

Prediabetes goes hand in hand with cardiovascular and renal risk factors

Data from the US NHANES show that a high proportion of adults with prediabetes also have cardiovascular and renal risk factors.

02-16-2018 | Nephropathy | News

Albuminuria regression associated with reduced CVD risk in patients with type 1 diabetes

Improvement in albuminuria is associated with a reduction in the risk for cardiovascular disease and mortality among patients with diabetic nephropathy, results of the FinnDiane study suggest.

02-13-2018 | Nephropathy | News

Clinical presentation of CKD may influence mortality risk

US research demonstrates that mortality rates have decreased over time among diabetes patients with elevated urinary albumin excretion, but have increased for those with low estimated glomerular filtration rate in the absence of albuminuria.

02-12-2018 | Diabetic foot | News

Predictors of diabetic foot amputation identified

Arterial disease and neuropathy, along with poor vision and reduced kidney function, are associated with a significantly increased risk for lower limb amputation in men with diabetes, US researchers report.

12-13-2017 | Cardiovascular outcomes | News

Prognostic value of UACR depends on availability of cardiac biomarkers

An increased urinary albumin to creatinine ratio is significantly and independently associated with an increased risk for cardiovascular outcomes in patients with type 2 diabetes, an analysis of SAVOR-TIMI 53 data shows.

11-10-2017 | Nephropathy | News

Salt restriction boosts losartan benefits in type 2 diabetes

Finding from the PROCEED trial show that dietary salt restriction helps to reduce albuminuria in patients with type 2 diabetes taking losartan, the investigators report in The Lancet Diabetes & Endocrinology.

11-01-2017 | Adolescents | News

No renal benefits of ACE inhibitor, statin treatment in adolescents with type 1 diabetes

Results of AdDIT show that treatment with an ACE inhibitor, a statin, or both does not protect against the increased albumin excretion that frequently occurs in patients with type 1 diabetes during adolescence.

10-30-2017 | Nephropathy | News

Blood pressure, aortic stiffness predict renal outcomes in type 2 diabetes patients

High ambulatory systolic blood pressure and increased aortic stiffness are associated with the development and progression of kidney disease among patients with type 2 diabetes, study results suggest.

09-27-2017 | Nephropathy | News

Kidney disease warning for type 1 diabetes patients

US researchers warn that some degree of kidney disease is “virtually universal” among patients who have been diagnosed with type 1 diabetes for a long time.

09-15-2017 | Physical activity | EASD 2017 | News

Exercise important for type 1 diabetes patients regardless of CKD

Physical activity is linked to lower mortality risk among patients with type 1 diabetes irrespective of whether they have comorbid chronic kidney disease, study results suggest.

09-13-2017 | GLP-1 agonists | EASD 2017 | News

Incretins research update

One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.

08-30-2017 | Liraglutide (T2DM) | News

LEADER renal analysis shows protective effect of liraglutide

Analysis of the renal outcomes of patients in the LEADER trial confirms that the glucagon-like peptide-1 analog liraglutide has a renoprotective effect in patients with type 2 diabetes and increased cardiovascular risk.

08-25-2017 | Cardiovascular outcomes | News

Poor outlook after stroke for type 1 diabetes patients

Nearly three-quarters of patients with type 1 diabetes have cardiovascular events and more than half die in the years following a stroke, a study shows.

08-18-2017 | Complications | News

Updated risk equations for type 2 diabetes complications published

Researchers have developed and validated new risk equations to help predict macrovascular and microvascular complications in patients with type 2 diabetes.

07-26-2017 | Linagliptin | News

No short-term renal benefits with linagliptin in early diabetic kidney disease

Linagliptin significantly improves glycemic control in individuals with type 2 diabetes and early-stage kidney disease, but fails to significantly ameliorate glomerular damage, show findings from the MARLINA-T2D trial.

07-04-2017 | Complications | News

June Cochrane review round-up

Here we provide an overview of the seven Cochrane reviews published in June that covered topics relating to diabetes, including glycemic control for prevention of renal failure, phototherapy for foot ulcers, and anti-vascular endothelial growth factor treatment for diabetic macular edema.

06-29-2017 | Empagliflozin | News

EMPA-REG analysis backs empagliflozin renoprotective effects

Further analysis of the EMPA-REG trial shows that treatment with empagliflozin improves urinary albumin excretion in patients with type 2 diabetes over the short and long term.

06-14-2017 | Canagliflozin | ADA 2017 | News

Integrated CANVAS: canagliflozin offers cardioprotection at amputation cost

The integrated results of the CANVAS and CANVAS-R studies show that canagliflozin reduces the risk for cardiovascular and renal events in patients with type 2 diabetes at high cardiovascular risk.

05-05-2017 | Lixisenatide | News

Support for lixisenatide in type 2 diabetes patients with renal impairment

Results of a post-hoc analysis suggest that the efficacy of lixisenatide is not compromised among patients with type 2 diabetes who have mild or moderate renal impairment.

04-03-2017 | Complications | News

Meta-analysis supports tight glycemic control for microvascular health

A meta-analysis from the Collaborators on Trials of Lowering Glucose group supports intensive glycemic control for improved microvascular outcomes in patients with type 2 diabetes.

03-30-2017 | Ketoacidosis | News

Acute kidney injury common in pediatric diabetic ketoacidosis

Almost two-thirds of children hospitalized with diabetic ketoacidosis develop acute kidney injury within 24 hours of hospitalization, study findings indicate.

03-03-2017 | Metabolic surgery | News

Prediabetics may gain most in long term from bariatric surgery

Research shows that the largest long-term reductions in microvascular complications around 20 years after bariatric surgery for obesity are seen among patients who had prediabetes at the time of surgery.

11-25-2016 | Nephropathy | News

Low BP could be renoprotective in type 1 diabetes

Observational data suggest that a low blood pressure target may still be necessary for patients with type 1 diabetes.

10-26-2016 | Complications | News | Article

Causes of death defined in young adults with type I diabetes

Mortality rates are high among adolescents and young adults with type I diabetes, with more than half caused by acute or chronic complications, researchers report.

10-18-2016 | Nephropathy | News

Kidney function drives CV outcomes in Type 2 diabetes

Baseline kidney function is the major predictor of cardiovascular outcomes in sitagliptin-treated patients with Type 2 diabetes, shows an analysis of the TECOS trial.

10-11-2016 | Nephropathy | News

Diabetic dyslipidaemia linked to nephropathy risk

The presence of diabetic dyslipidaemia may explain why patients with Type 2 diabetes develop kidney disease despite good risk factor control, say researchers.

09-16-2016 | Cardiovascular outcomes | News

Favourable cardiovascular safety profile for semaglutide

Semaglutide significantly reduces the likelihood of adverse cardiovascular outcomes among patients with Type 2 diabetes at high cardiovascular risk, the SUSTAIN-6 study shows.

09-08-2016 | Nephropathy | News | Article

Lifelong benefits from early multifactorial diabetes intervention

Nearly 2 decades after the launch of the Steno-2 study, patients with complicated diabetes given intensive multifactorial treatment have gained nearly 8 years of life, say the researchers.

Image Credits